未來已來：經導管主動脈瓣置換術在中低危患者的臨床應用現狀和前景_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

施浩 , 王首正 ,  謝涌泉

中國醫學科學院北京協和醫學院國家心血管病中心中國醫學科學院阜外醫院（北京 100037）;

Corresponding?author：

謝涌泉, Email: xieyq007@qq.com

Keywords：

主動脈瓣置換術，經導管; 臨床研究; 介入

DOI：

10.7507/1007-4848.201909009

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 施浩, 王首正, 謝涌泉. 未來已來：經導管主動脈瓣置換術在中低危患者的臨床應用現狀和前景. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2019, 26(11): 1060-1062. doi: 10.7507/1007-4848.201909009 Copy

1.	Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for themanagement of patients with valvular heart disease. J Am Coll Cardiol, 2014, 63(22): 2438-2488.
2.	Samir R Kapadia, Martin B Leon, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 2015, 385(9986): 2485-2491.
3.	Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2016, 374(17): 1609-1620.
4.	張源, 潘文治, 周達新, 等. 國內首例經導管主動脈瓣置入 Edwards SAPIEN 3 瓣膜. 中國介入心臟病學雜志, 2019, 27(4): 238-240.
5.	Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardio, 2017, 70(2): 252-289.
6.	Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J, 2017, 38(36): 2739-2791.
7.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
8.	Jeffrey J. Popma, Michael Deeb, et al Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
9.	van Rosendael PJ, Delgado V, Bax JJ, et al. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J, 2018, 39(21): 2003-2013.
10.	Husser O, Pellegrini C, Kessler T, et al. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv, 2016, 9(3): 244-254.
11.	Vahanian A, Urena M, Walther T, et al. Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial. EuroIntervention, 2016, 12(2): e235-e243.
12.	Yoon SH, Sharma R, Chakravarty T, et al. Clinical outcomes and prognostic factors of transcatheter aortic valve implantation in bicuspid aortic valve patients. Ann Cardiothorac Surg, 2017, 6(5): 463-472.

1. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for themanagement of patients with valvular heart disease. J Am Coll Cardiol, 2014, 63(22): 2438-2488.
2. Samir R Kapadia, Martin B Leon, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 2015, 385(9986): 2485-2491.
3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2016, 374(17): 1609-1620.
4. 張源, 潘文治, 周達新, 等. 國內首例經導管主動脈瓣置入 Edwards SAPIEN 3 瓣膜. 中國介入心臟病學雜志, 2019, 27(4): 238-240.
5. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardio, 2017, 70(2): 252-289.
6. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J, 2017, 38(36): 2739-2791.
7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
8. Jeffrey J. Popma, Michael Deeb, et al Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
9. van Rosendael PJ, Delgado V, Bax JJ, et al. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J, 2018, 39(21): 2003-2013.
10. Husser O, Pellegrini C, Kessler T, et al. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv, 2016, 9(3): 244-254.
11. Vahanian A, Urena M, Walther T, et al. Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial. EuroIntervention, 2016, 12(2): e235-e243.
12. Yoon SH, Sharma R, Chakravarty T, et al. Clinical outcomes and prognostic factors of transcatheter aortic valve implantation in bicuspid aortic valve patients. Ann Cardiothorac Surg, 2017, 6(5): 463-472.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

未來已來：經導管主動脈瓣置換術在中低危患者的臨床應用現狀和前景

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content